Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPTN 082: PrEP Adherence in Young African Women
NCT02732730Phase 4Completed
- Sponsor
- HIV Prevention Trials Network
- Start
- Oct 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (2 arms), sponsored by HIV Prevention Trials Network. Primary endpoint: Number of Participants With High Adherence at Six Months at 6 months. Started Oct 2016; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02732730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02732730.